Email
Print
Ebola Drug & Vaccine Market - Forecast(2024 - 2030)
Ebola Drug & Vaccine Market Overview
Ebola Drug & Vaccine Market Size is estimated to reach $223.7 million
by 2027 and is poised to grow at a CAGR of 12.8% over
the forecast period of 2022-2027. Ebola has emerged as a serious threat to
humanity. The origin of Ebola is unknown, scientists considered the Ebola virus
is transmitted from animals to humans. The species Zaire ebolavirus (EBOV) is
the most lethal, with case fatality rates of 70–90% if left untreated. Zaire ebolavirus (EBOV) is responsible for
the majority of recorded Ebola Virus Disease (EVD) outbreaks. Fever, severe
headaches and joint pain, weakness and fatigue, soar throat and loss of
appetite are some common symptoms of Ebola virus infections. The lack of an
effective treatment for Ebola is the main factor driving the worldwide market
for Ebola vaccines, making a cure one of the most urgent and financially
rewarding global needs. To produce an effective Ebola vaccine various
components are used such as an immunologic adjuvant that enhances the magnitude,
induction or durability of antigen-specific immunogenicity. It is used in
combination with specific vaccine antigens, adenoviridae, Vesiculovirus and glycoprotein
to produce vaccines for the Ebola virus. For instance, the ChAd3-EBO-Z Ebola vaccine
consists of a recombinant replication-defective Chimpanzee adenovirus type 3
(ChAd3) derived vector encoding the Ebola virus Zaire (EBOV-Z) glycoprotein. Between
23 April and 3 July 2022, a total of 5 (4 confirmed and 1 probable) cases of
EVD, including 5 deaths (case fatality ratio 100%), were reported from 3 health
areas in Equateur province. Such a high fatality rate for the Ebola virus and the urgent
need for an Ebola treatment drive growth of the Ebola Drug and Vaccine Industry
over the forecast period 2022-2027.
Ebola Drug & Vaccine Market Report Coverage
The “Ebola Drug & Vaccine Market Report - Forecast
(2022-2027)" by Industry ARC, covers an in-depth analysis of the following
segments in the Ebola Drug & Vaccine Market.
Key Takeaways
- Geographically, North America held a dominant market share in the year 2021, owing to the high investment in research and developments for the production of vaccines. The contribution of the National Institute of Allergy and Infectious Disease with funding and support drives research and development for the production of the new vaccine in this region and propels the growth of the Ebola Drug & Vaccine Market Size.
- The Ebola Drug & Vaccine Market is predicted to increase owing to the growing outbreak of the Ebola virus in recent years and the high mortality rate with Ebola infections.
- However, the high cost required for research and development and the uncertain nature of the Ebola virus may limit the Ebola drug and vaccine industry growth over the forecast period 2022-2027.
- A detailed analysis of strengths, weaknesses, opportunities and threats will be provided in the Ebola Drug & Vaccine Market Report.
Ebola Drug & Vaccine: Market Share (%) by region, 2021
For More Details On this report - Request For Sample
Ebola Drug & Vaccine Market Segment Analysis - by Strain Type
Ebola Drug & Vaccine Market based on strain type can be further
segmented into Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus. The zaire strain segment held a dominant market share in
the year 2021 and is estimated to grow with the
fastest CAGR of 13.2% over the forecast period 2022-2027. This is
owing to the high mortality rate of this strain. The mortality rate of zaire
Ebola virus is up to 90%. In 2020, the Democratic Republic of Congo witnessed
the second largest EVD outbreak in the world, resulting in 3481 cases and 2299
mortalities. Such a high mortality rate of the Ebola Zaire strain surges demand better medication to prevent and treat Ebola virus infection cases. Such high
demand for Drugs and Vaccines for the Treatment and Prevention of the Ebola
virus drives the growth of the Ebola Drug & Vaccine Market.
Ebola Drug & Vaccine Market Segment Analysis - by End-user
Ebola Drug & Vaccine Market based on the End User can be further
segmented into Hospitals, Ambulatory Surgical Centers, Specialised Clinics,
Army Camps and Others. The hospital segment held a dominant market share in the
year 2021. This is owing to the growing admission for treatment and diagnosis
of various infectious diseases in hospitals. According to a research paper
published in Springer Nature, from study of infectious and parasitic disease
(IPD) hospital admissions (HA) in England and Wales between 1999 and 2019,
found that IPD hospital admissions for a diverse range of reasons increased by
349.9, from 290.25 in 1999 to 1305.88 in 2019 per 100,000 people.
Such growing admission owing to various infectious diseases surge demand for
hospitals to treat and drive the growth of the Ebola Drug & Vaccine Market Share.
However, Ambulatory Surgical Centers is estimated
to grow with the fastest CAGR of 13.8% over the forecast period
2022-2027. This is owing to the high burden on hospitals and the high
waiting period for treatment surge demand for ambulatory surgical centers.
Ambulatory surgical centers provide quick services and are available at the given time
with the appointment. Owing to the busy life schedules demand for ambulatory surgical
centers is increased in recent years, which are effectively utilized for diagnosis,
treatment and vaccination. Such growing demand for ambulatory surgical centers fuels the growth of the Ebola Drug & Vaccine Market Share over the forecast period
2022-2027.
Ebola Drug & Vaccine Market Segment Analysis - by Geography
The Ebola Drug & Vaccine Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. The rest of the World held a dominant market share of 40% in the year 2021. This is owing to the Ebola virus origin which is from the Ebola River in the Democratic Republic of Congo, which is located in Central Africa. Also, the Democratic Republic of Congo suffered from most of the Ebola outbreaks. According to World Health Organisation (WHO) release, in May 2021, 11 confirmed cases and 1 probable case, 6 deaths and 6 recoveries were recorded in 4 health zones in North Kivu since 7 February 2021. According to a press release by the Ministry of Health (MoH) of the Democratic Republic of the Congo (DRC), between 8 October to 16 December, a total of 11 cases (eight confirmed, three probable) including nine deaths and two survivors have been reported from Beni Health Zone. Such a growing outbreak of Ebola Virus surge demand for Ebola Drug and Vaccine fuel the growth of the Ebola Drug & Vaccine Market share over the forecast period 2022-2027.
Furthermore, North America is estimated to grow with the fastest CAGR over the forecast period 2022-2027. This is owing to growing research for the development of treatment against the Ebola virus. Additionally, the rising number of immigrants from African countries to developed nations such as the United States increases the chances of infection with the Ebola Virus. According to a report published by migration policy in May 2022, about 2.1 million sub-Saharan African immigrants resided in the United States in 2019, representing 5% of the total foreign-born population of 44.9 million. Such growing immigration from African countries increases the risk of Ebola infection and surges demand for research and discoveries of new treatments with high immunologic adjuvant for strong immune response in people receiving the vaccine driving the growth of the Ebola Drug and Vaccine Market Size.
Ebola Drug & Vaccine Market Drivers
Growing Prevalence of Infectious Diseases Drive Market.
The demand for Ebola drugs and vaccines is on the spike
owing to the growing prevalence of infectious diseases and their high mortality
rate. According to thereat report published by the European Center for Disease
Prevention and Control (ECDC), for the first week of January 2022, Albania, Israel,
North Macedonia, Norway, the Russian Federation and Sweden reported widespread
influenza activity and/or medium influenza intensity from 27 December
2021 - 2 January 2022. Also, 6 countries reported seasonal influenza activity
above the 10% positivity threshold in sentinel primary care: Armenia (78%),
Israel (68%), Sweden (36%), France (33%) the Republic of Moldova (24%) and
Albania (18%). Additionally, in 2021, 2,25,696 cases of Chikungunya virus
disease were reported, the majority from Brazil (127 487) and India (91 477).
Such growing cases of infectious disease and high prevalence rate increase
demand for various drugs, vaccines and treatments which fuel the growth of the Ebola
Drug and Vaccine Industry over the forecast period 2022-2027.
Continuous R&D Conducted by Key Market Players for Production of Novel Vaccines and Drugs is Anticipated to Drive Market Growth.
The development for the production of a new Ebola Vaccine and its combination elements like adenoviridae and Vesiculovirus is very low. According to the Center for Disease Control and Prevention (CDC), there are currently two treatments approved by the U.S. Food and Drug Administration (FDA) to treat EVD caused by the Ebola virus, species Zaire ebolavirus, in adults and children. The first drug approved in October 2020, Inmazeb, is a combination of three monoclonal antibodies. The second drug, Ebanga, is a single monoclonal antibody and was approved in December 2020. Regeneron, the producer of Inmazeb expects to deliver an established number of treatment doses for 6 years and received compensation of approximately $10 million in 2021 and an average of $67 million per year for each of the next five years (2022-2027). Such limited approved treatments for the Ebola virus drive the growth of the Ebola Drug and Vaccine Industry over the forecast period 2022-2027.
Ebola Drug & Vaccine Market Challenges
High Development Cost and Changing Nature of Virus is Hampering Market Growth
The cost for the development of vaccines and drugs is related to the cost of the constituent's availability and financial support for high investment. The cost for development of vectors such as recombinant replication-defective Chimpanzee adenovirus type 3 (ChAd3) with incorporated Ebola virus Zaire (EBOV-Z) glycoprotein, with use of immunologic adjuvant to maintaining high immunogenicity is very cost extensive task. Also, the prices of combinations of ingredients like antigens, adenoviridae and Vesiculovirus are also costly. The immunogenicity of vaccines is very important as the work of vaccines is depend on it, which measures the type of immune responses that the vaccine generates and their magnitude over time. Owing to such high production costs the cost of Ebola vaccination has increased. According to a research paper published in the Journal of Medicine and Economics, in July 2022, the cost of Ebola vaccination resulted in increased total costs while decreasing directly proportional to effectiveness (DALYs prevented). Averting a DALY was estimated to cost $73.43, $94.33, $101.63 and $666.38 in Uganda, DRC, Liberia and Sierra Leone, respectively. Such a high cost of vaccine production and vaccination may hamper Ebola Drug and Vaccine Industry growth over the forecast period 2022-2027.
Ebola Drug & Vaccine Industry Outlook
Product launches, mergers and acquisitions, joint ventures and
geographical expansions are key strategies adopted by players in the Ebola Drug & Vaccine Market. The top 10 companies in the Ebola Drug & Vaccine Market are:
- Arbutus Biopharma
- GlaxoSmithKline
- Johnson & Johnson Services Inc.
- Hemispherx Biopharma Inc.
- BioCryst Pharmaceuticals Inc.
- NanoViricides Inc.
- NewLink Genetics Corporation
- Chimerix Inc.
- Sarepta Therapeutics
- Mapp Biopharmaceutical Inc
Recent Developments
- In July 2022, Arbutus Biopharma Corporation, announced a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, announced to continue dosing patients in the Phase 2a triple combination clinical trial evaluating its proprietary RNAi therapeutic, AB-729, VBR and nucleus(t)ide analog (NA) therapy for the treatment of patients with chronic HBV infection (cHBV). While their partner in the project Assembly Biosciences decided to discontinue the development of its investigational hepatitis B virus core inhibitor candidate vebicorvir (VBR).
- In July 2022, GlaxoSmithKline announced it has completed the acquisition of Sierra Oncology, Inc. California-based biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer. The acquisition builds on the company’s expertise in hematology and aligns with GSK’s strategy of building a strong portfolio of specialty medicines and vaccines.
- In June 2022, BioCryst Pharmaceuticals announced the company has entered into an exclusive collaboration with Pint Pharma GmbH to register and promote ORLADEYO (berotralstat) in the pan-Latin America region. Under the terms of the agreement, Pint Pharma will be responsible for obtaining and maintaining all marketing authorizations and for commercializing ORLADEYO in the pan-LATAM region.
Relevant Titles
Report Code: HCR 0711
Report Code: HCR 10303
Report Code: HCR 1211
For more Lifesciences and Healthcare Market reports, please click here